RESUMO
In 2 patients, to promote skin wound/lesion repair we used fibrin-platelet glue combined with HLA compatible (2 mismatches accepted) buffy coats containing CD 34+ cord blood cells. The fibrin platelet glue was prepared with autologous apheresis platelets and cryoprecipitate. The original product was divided into 3 and 4 aliquots respectively for a correspondent number of applications. At each application, the margins of the lesion were infiltrated with 3 ml of cord blood buffy coat, containing 30 x 10(3) CD 34+ cells. No graft versus tissue reaction was seen in our patients in a follow-up of 3-7 months. The level of improvement, scored arbitrarily from 0 to 4, was 3 and 4, respectively. Our conclusion is that the use of cord blood cells along with fibrin platelet glue is of clinical interest.
Assuntos
Sangue Fetal/citologia , Células-Tronco/citologia , Cicatrização , Idoso , Idoso de 80 Anos ou mais , Antígenos CD34/biossíntese , Remoção de Componentes Sanguíneos , Plaquetas/metabolismo , Feminino , Adesivo Tecidual de Fibrina/química , Antígenos HLA/química , Teste de Histocompatibilidade , Humanos , Masculino , Fatores de Tempo , Adesivos Teciduais/químicaRESUMO
To promote wound healing, we used autologous fibrin-platelet glue in 14 patients with skin and soft tissue losses caused by recent trauma or chronic pathology. The level of improvement was scored, arbitrarily, from 0 to 4. Very favourable results (score 3-4) were seen in 11 out of 14 patients. The glue preparation is very easy, inexpensive and creates excellent and stable hemostasis. From a general point of view, we have confirmed the utility of fibrin-platelet glue in terms of reduced infections and length of hospital stay.
Assuntos
Plaquetas , Adesivo Tecidual de Fibrina/uso terapêutico , Procedimentos de Cirurgia Plástica/métodos , Úlcera Cutânea/cirurgia , Lesões dos Tecidos Moles/cirurgia , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The paper describes the use of aminoglucoside amikacin over 3 years in a group of 187 patients for the topical treatment of skin lesions extending over a maximum 10% of body surface area. The use of amikacin for topical treatment was chosen on the basis of clinical factors; in the majority of cases these were associated to poor circulation in the affected region which created uncertainty as to whether an efficacious dose would be provided by intravenous administration.
